N-Acetylcysteine in Psychiatric Disorders

N-Acetylcysteine (NAC) is a derivative of the amino acid cysteine and serves principally as a precursor to the antioxidant glutathione. In the central nervous system, NAC has been shown to modulate redox balance, attenuate inflammatory signalling and influence glutamatergic neurotransmission. Preclinical studies indicate that NAC can protect neurons against oxidative damage, regulate microglial activation and counteract stress-related behavioural deficits. Clinically, NAC has been explored as an adjunctive therapy across a spectrum of psychiatric conditions, including schizophrenia, bipolar depression, obsessive-compulsive and related disorders, substance use disorders and post-traumatic stress disorder. Typical oral dosing ranges between 2 000 and 3 000 mg per day, with a favourable safety and tolerability profile. Despite promising results in terms of negative symptom reduction in schizophrenia and craving attenuation in addiction, outcomes in mood and trauma-related disorders remain mixed. Variability in trial design, patient selection and biomarker assessment underscores the need for well-powered studies with standardised endpoints. Globally, the potential to repurpose a readily accessible and low-cost agent such as NAC offers significant public health implications, particularly in low-resource settings where novel therapeutics are less available.

Research from Nature Portfolio

No recent Nature Portfolio content available.

N-Acetylcysteine in Psychiatric Disorders publication trend

The graph below shows the total number of articles in n-acetylcysteine in psychiatric disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Oxidative stress: An imbalance between free radical production and antioxidant defences leading to cellular damage.

Glutathione: A tripeptide antioxidant critical for neutralising reactive oxygen species and maintaining redox homeostasis.

Microglia: Resident immune cells of the central nervous system that mediate inflammatory responses.

Adjunctive therapy: A treatment given in addition to the primary or standard therapy to enhance efficacy.

Standardised mean difference: A statistical measure that quantifies the effect size across studies using different scales.

References

1. N-Acetylcysteine Suppresses Microglial Inflammation and Induces Mortality Dose-Dependently via Tumor Necrosis Factor-α Signaling. International Journal of Molecular Sciences (2023).
2. A multi-centre, double-blind, 12-week, randomized, placebo-controlled trial of adjunctive N-Acetylcysteine for treatment-resistant PTSD. Psychiatry Research (2023).
3. Mitochondrial modulators in the treatment of bipolar depression: a systematic review and meta-analysis. Translational Psychiatry (2022).
4. N‐Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence. BioMed Research International (2018).